| 摘要 |
The water-soluble calcitonins and the water-soluble pharmaceutically-acceptable compounds of acidic nature which are effective against Paget's disease and which contain at least two acidic groups separated by not more than two carbon atoms act synergistically in inhibiting a pathological increased calcium metabolism rate (including the solubilization of bone calcium which occurs in Paget's disease). The components in combination, when administered in respectively preferred amounts, inhibit or arrest loss of calcium by the bones of the body with less severe side effects than those caused by equivalent therapeutic doses of the calcitonin alone or by equivalent therapeutic doses of the compounds of acidic nature alone. |
